Dr. Benjamin J. Thomas, MD
Ophthalmology (Ophthalmology Physician)
- Medicare participating
At a glance
- In the NPI registry since
- 2009
- Medicare patients seen, 2024
- 985
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2009Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Ophthalmology Physician primary
FL license ME127512 · GA license 75932 -
Retina Specialist (Ophthalmology) Physician
FL license ME127512 · GA license 75932
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare patients and services
- Medicare patients, 2024
- 985
- Services billed
- 28,228
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Injection, faricimab-svoa, 0.1 mg | 5,820 | 23 |
| Imaging of retina | 2,517 | 974 |
| Injection, aflibercept, 1 mg | 2,134 | 215 |
| Injection of drug into eye | 1,500 | 335 |
| Photography of the retina | 1,115 | 874 |
| Injection, ranibizumab, 0.1 mg | 886 | 40 |
| Established patient office or other outpatient visit, 20-29 minutes | 708 | 366 |
| Extended exam of the back part of the eye with optic nerve drawing | 620 | 388 |
| Established patient complete exam of visual system | 515 | 506 |
| Established patient problem focused exam of visual system | 431 | 351 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisolone Acetate Other prescribers in Jacksonville, FL | 286 |
| Ketorolac Tromethamine Other prescribers in Jacksonville, FL | 131 |
| Dorzolamide-Timolol (dorzolamide hcl/timolol maleat) Other prescribers in Jacksonville, FL | 99 |
| Latanoprost Other prescribers in Jacksonville, FL | 85 |
| Brimonidine Tartrate Other prescribers in Jacksonville, FL | 81 |
| Gentamicin Sulfate Other prescribers in Jacksonville, FL | 81 |
| Atropine Sulfate | 67 |
| Eylea (aflibercept) | 57 |
| Dorzolamide Hcl Other prescribers in Jacksonville, FL | 52 |
| Timolol Maleate Other prescribers in Jacksonville, FL | 39 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 7 companies reported 13 payments worth $4,074 in total to this clinician.
| Regeneron Healthcare Solutions, Inc. | $2,286 |
|---|---|
| AbbVie Inc. | $1,624 |
| Apellis Pharmaceuticals, Inc. | $50.75 |
| Alcon Vision LLC | $46.43 |
| Astellas Pharma US Inc | $30.28 |
| Genentech USA, Inc. | $20.75 |
| Harrow Eye, LLC | $15.55 |
| Compensation for services other than consulting (speaking, faculty) | $2,192 |
|---|---|
| Consulting Fee | $1,600 |
| Food and Beverage | $282 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. Jun 20, 2025 | Compensation for services other than consulting (speaking, faculty) EYLEA HD · OPHTHALMOLOGY | $2,192 |
| AbbVie Inc. Feb 5, 2025 | Consulting Fee OZURDEX · EYE CARE | $1,600 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 8 industry-funded studies in 2025, from 4 companies. The companies reported $1,004,399 in research payments for these studies, mostly to the institutions running them.
- A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)
Regeneron Pharmaceuticals, Inc. · Active, not recruiting · NCT06491914 - A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
Regeneron Pharmaceuticals, Inc. · Recruiting · NCT06541704 - Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease
Regeneron Pharmaceuticals, Inc. · Completed · NCT04429503 - Phase 2 study to investigate RO7200220 in diabetic macular edema
Roche Tcrc, Inc. - CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitre…
Boehringer Ingelheim International GmbH - A study to investigate RO7200394 as novel intravitreal treatment for central retinal vein occlusion
Roche Tcrc, Inc. - BI 771716 - SRD and MD in geographic atrophy patients
Boehringer Ingelheim International GmbH - BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration
Bayer HealthCare Pharmaceuticals Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.